



## Mersana Therapeutics to Participate in Investor Conferences in September

August 31, 2017

CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- [Mersana Therapeutics, Inc.](http://www.mersana.com) (NASDAQ:MRSN) today announced that Anna Protopapas, President and Chief Executive Officer, will participate in three upcoming investor conferences in September. Details are as follows:

### **Baird 2017 Global Healthcare Conference**

Date/time: Wednesday, September 6<sup>th</sup> at 3:10 p.m. E.T.  
Location: New York, NY

### **Cantor Fitzgerald Global Healthcare Conference**

Date/time: Wednesday, September 27<sup>th</sup> at 3:25 p.m. E.T.  
Location: New York, NY

### **Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology**

Date/time: Thursday, September 28<sup>th</sup> at 8:00 a.m. E.T.  
Location: New York, NY

Live webcasts of the presentations will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). Archived replays will be available for approximately 60 days following the presentations.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana's leading platform to advance their ADC pipelines.

#### Media Contact

Paul Kidwell [paulkidwell@comcast.net](mailto:paulkidwell@comcast.net)  
617-680-1088

#### Investors Contact

Stern Investor Relations, Inc.  
Christina Tartaglia [Christina@sternir.com](mailto:Christina@sternir.com)  
(212) 362-1200

 [Primary Logo](#)

Mersana Therapeutics